Pomalidomide is a cancer medicine that promotes an immune response to help slow tumor growth. It is used in combination with dexamethasone to treat people with relapsed/refractory multiple myeloma who have received at least two prior medicines to treat their myeloma (including a type of medicine known as a proteasome inhibitor and lenalidomide).
SparkCures ID | 5 |
---|---|
Developed By | Celgene Corporation, a wholly owned subsidiary of Bristol Myers Squibb |
Brand Name | Pomalyst® |
Generic Name | Pomalidomide |
Additional Names | CC-4047, Actimid |
Treatment Classifications |
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.
The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
The following is a listing of clinical trials for patients with Smoldering Myeloma.
There are no resources, links or videos to display for this treatment.